Biopharma
ByCan Ianalumab Anchor Novartis’ Next Growth Cycle as Patent Pressures Mount?
23 Jan 2026 Executive Summary Novartis has secured Breakthrough Therapy designation for ianalumab, a late-stage immunology asset, reinforcing…
Is JPM 2026 the Moment Biopharma Finally Reset Its Strategy?
January 2026 — San Francisco | Global — The 44th Annual J.P. Morgan Healthcare Conference (JPM 2026) marked…
How Might Trump’s Strategic Healthcare Proposal Impact Innovation and Affordability?
January 22, 2026 — Global — BioNexAI Market Insights reports that U.S. President Donald J. Trump has introduced…
Is Novartis Bolstering Its Radioligand Oncology Pipeline at JPM 2026 with a Radioligand Peptide Program Acquisition?
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a global license and…
Can Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Is Novo Nordisk Positioning Cell-Based Therapies as the Future of Diabetes Care?
23 January 2026 Executive Summary Novo Nordisk has expanded its strategic collaboration with Canadian biotech Aspect Biosystems, intensifying…
